$PGEN News

Precigen (PGEN) Stock May Be Fully Priced On Its Huge 3 Year Run

Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base

Precigen (PGEN) Draws Attention To Papzimeos, Is The Valuation Upside Already Priced In?

Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy?

Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

Precigen: Has To Grow Into Its Valuation

Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement

HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $14 Price Target

Precigen Inc (NASDAQ:PGEN) Flashes Perfect Technical Rating and Explosive Sales Growth in Minervini Screen

Precigen: Entering The Oncology 'Sweet Spot'